Sanofi unwilling to increase bid with Genzyme

NEW YORK Biotech drug maker Genzyme’s takeover by French drug maker Sanofi-Aventis may have run into trouble, according to published reports.

Bloomberg reported Wednesday that Sanofi was unwilling to raise its offer of $70 per share for Genzyme, a Cambridge, Mass.-based company that has carved a niche for itself by manufacturing treatments for such rare genetic disorders as Fabry disease and Pompe disease but lately has been dogged by manufacturing problems.

Sanofi’s current offer stands at $69 a share, a total of around $17.6 billion, according to Bloomberg.

Recommended stories

Login or Register to post a comment.